Innovent registers Phase 1 trial of IBI3043 in advanced solid tumors
Innovent Biologics has listed a new Phase 1 study of IBI3043 for unresectable or metastatic solid tumors, not yet recruiting as of October 29, 2026.
Innovent Biologics had one new registry item this week.
- IBI3043, an investigational drug, is being tested in a Phase 1, multicenter, open-label study for participants with unresectable, locally advanced, or metastatic solid tumors.1 The trial is not yet recruiting,1 with an estimated enrollment of 604 participants,1 and the study is designed in two parts, a Phase 1 dose escalation and a Phase 2 dose expansion.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.